CN112076176A - 一种普瑞巴林胶囊及其制备方法 - Google Patents
一种普瑞巴林胶囊及其制备方法 Download PDFInfo
- Publication number
- CN112076176A CN112076176A CN202011120398.4A CN202011120398A CN112076176A CN 112076176 A CN112076176 A CN 112076176A CN 202011120398 A CN202011120398 A CN 202011120398A CN 112076176 A CN112076176 A CN 112076176A
- Authority
- CN
- China
- Prior art keywords
- pregabalin
- capsule
- microcrystalline cellulose
- silicified microcrystalline
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 93
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 91
- 239000002775 capsule Substances 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title description 50
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000002245 particle Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 22
- 238000009826 distribution Methods 0.000 claims abstract description 19
- 238000011049 filling Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 230000004580 weight loss Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 abstract description 31
- 239000000463 material Substances 0.000 abstract description 18
- 238000011068 loading method Methods 0.000 abstract description 10
- 238000009776 industrial production Methods 0.000 abstract description 8
- 108010010803 Gelatin Proteins 0.000 abstract description 6
- 229920000159 gelatin Polymers 0.000 abstract description 6
- 239000008273 gelatin Substances 0.000 abstract description 6
- 235000019322 gelatine Nutrition 0.000 abstract description 6
- 235000011852 gelatine desserts Nutrition 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 5
- 238000003860 storage Methods 0.000 abstract description 3
- 238000004132 cross linking Methods 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 39
- 239000000203 mixture Substances 0.000 description 15
- 238000009472 formulation Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000007906 compression Methods 0.000 description 10
- 230000006835 compression Effects 0.000 description 10
- 230000001186 cumulative effect Effects 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 229960001375 lactose Drugs 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010828 elution Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002584 ketoses Chemical class 0.000 description 2
- 229940009697 lyrica Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组分 | 比例% | 每粒用量mg |
普瑞巴林 | 25.0 | 25.0 |
硅化微晶纤维素 | 75.0 | 75.0 |
流动性 | 压缩指数(%) |
极好 | ≤10 |
好 | 11~15 |
一般 | 16~20 |
可通过 | 21~25 |
差 | 26~31 |
很差 | 32~37 |
非常差 | >38 |
流动性 | 休止角(°) |
非常好 | 25~30 |
很好 | 31~35 |
好-无需加入辅助物 | 36~40 |
可接受-需要加入辅助物 | 41~45 |
差 | 46~55 |
非常差 | 55~65 |
非常非常差 | >66 |
USP溶出方法 | 转速rpm | 溶出介质 | 容积(mL) |
II(浆法)沉降篮 | 50 | 0.06N盐酸溶液 | 900 |
Claims (5)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910997647.9A CN110613694A (zh) | 2019-10-18 | 2019-10-18 | 一种普瑞巴林胶囊及其制备方法 |
CN2019109976479 | 2019-10-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112076176A true CN112076176A (zh) | 2020-12-15 |
CN112076176B CN112076176B (zh) | 2021-12-28 |
Family
ID=68926031
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910997647.9A Pending CN110613694A (zh) | 2019-10-18 | 2019-10-18 | 一种普瑞巴林胶囊及其制备方法 |
CN202011120398.4A Active CN112076176B (zh) | 2019-10-18 | 2020-10-19 | 一种普瑞巴林胶囊及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910997647.9A Pending CN110613694A (zh) | 2019-10-18 | 2019-10-18 | 一种普瑞巴林胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN110613694A (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110613694A (zh) * | 2019-10-18 | 2019-12-27 | 杭州百诚医药科技股份有限公司 | 一种普瑞巴林胶囊及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014280A1 (en) * | 2006-07-17 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Amorphous pregabalin and process for the preparation thereof |
WO2010115612A2 (en) * | 2009-04-10 | 2010-10-14 | Synthon B.V. | Pregabalin compositions |
CN104771761A (zh) * | 2015-03-19 | 2015-07-15 | 深圳国源国药有限公司 | 一种创新药用辅料硅化微晶纤维素及其制备方法 |
CN105434395A (zh) * | 2015-12-31 | 2016-03-30 | 常州市阳光药业有限公司 | 普瑞巴林胶囊及其制备方法 |
CN105520918A (zh) * | 2015-12-31 | 2016-04-27 | 常州市阳光药业有限公司 | 普瑞巴林胶囊 |
CN106333928A (zh) * | 2016-08-31 | 2017-01-18 | 湖州展望药业有限公司 | 一种硅化微晶纤维素及其制备方法 |
CN110613694A (zh) * | 2019-10-18 | 2019-12-27 | 杭州百诚医药科技股份有限公司 | 一种普瑞巴林胶囊及其制备方法 |
-
2019
- 2019-10-18 CN CN201910997647.9A patent/CN110613694A/zh active Pending
-
2020
- 2020-10-19 CN CN202011120398.4A patent/CN112076176B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080014280A1 (en) * | 2006-07-17 | 2008-01-17 | Glenmark Pharmaceuticals Limited | Amorphous pregabalin and process for the preparation thereof |
WO2010115612A2 (en) * | 2009-04-10 | 2010-10-14 | Synthon B.V. | Pregabalin compositions |
CN104771761A (zh) * | 2015-03-19 | 2015-07-15 | 深圳国源国药有限公司 | 一种创新药用辅料硅化微晶纤维素及其制备方法 |
CN105434395A (zh) * | 2015-12-31 | 2016-03-30 | 常州市阳光药业有限公司 | 普瑞巴林胶囊及其制备方法 |
CN105520918A (zh) * | 2015-12-31 | 2016-04-27 | 常州市阳光药业有限公司 | 普瑞巴林胶囊 |
CN106333928A (zh) * | 2016-08-31 | 2017-01-18 | 湖州展望药业有限公司 | 一种硅化微晶纤维素及其制备方法 |
CN110613694A (zh) * | 2019-10-18 | 2019-12-27 | 杭州百诚医药科技股份有限公司 | 一种普瑞巴林胶囊及其制备方法 |
Non-Patent Citations (3)
Title |
---|
刘文主编: "《药用高分子材料学》", 30 June 2017, 中国中医药出版社 * |
董志江等: "硅化微晶纤维素的研究进展", 《中国医药工业杂志》 * |
韦超等主编: "《药剂学》", 31 August 2012, 河南科学技术出版社 * |
Also Published As
Publication number | Publication date |
---|---|
CN110613694A (zh) | 2019-12-27 |
CN112076176B (zh) | 2021-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112076176B (zh) | 一种普瑞巴林胶囊及其制备方法 | |
CN104306344B (zh) | 一种阿齐沙坦片剂及其制备工艺 | |
CN113164394B (zh) | 一种维拉佐酮固体分散体及其制备方法 | |
CN103830192A (zh) | 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法 | |
CN114288257A (zh) | 一种马来酸氟伏沙明片剂及其制备方法 | |
EP2612659B1 (en) | Panaxatriol saponins enteric pellet, capsule comprising same and method for preparing same | |
CN108030924B (zh) | 一种高稳定性阿瑞匹坦组合物的制备方法 | |
CN108066312B (zh) | 一种帕博西尼药物组合物及其制备方法 | |
CN102846575A (zh) | 硝苯地平缓释片及其制备方法 | |
CN102764254B (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
CN109908104B (zh) | 一种阿莫西林胶囊及其制备方法 | |
CN112023056B (zh) | 一种氟康唑药物组合物及其制备方法 | |
WO2016029494A1 (zh) | 微晶纤维素在制备美索舒利制剂中的用途及其制备方法 | |
CN113827576B (zh) | 一种活性成分为草酸纳洛解的药物组合物及制备方法 | |
CN103356495B (zh) | 一种来曲唑片剂及其制备方法 | |
CN108836973A (zh) | 二甲双胍格列本脲胶囊及其制备方法 | |
CN112843007A (zh) | 一种奥拉帕利片 | |
CN112315914A (zh) | 一种来那度胺药物组合物及其制备方法 | |
CN107496369A (zh) | 一种胞磷胆碱钠片及其粉末直接压片制备方法 | |
CN113694028A (zh) | 一种伏立康唑干混悬剂的制备方法 | |
CN112245402A (zh) | 一种吲达帕胺片及其制备方法 | |
CN106890146A (zh) | 一种磷酸奥司他韦分散片及其制备方法 | |
CN106822018A (zh) | 一种布洛芬缓释片及其制备方法 | |
CN110638764A (zh) | 一种坎地沙坦酯速释小丸 | |
CN106822026A (zh) | 一种新的阿莫西林胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Lou JinFang Inventor after: Chen Xiaoping Inventor after: Li Liuyang Inventor after: Zou Yonghua Inventor after: Lu Qinxia Inventor after: Ba Wenjing Inventor after: Pan Chen Inventor after: Xiao yanru Inventor after: Shen Ximing Inventor before: Chen Xiaoping Inventor before: Li Liuyang Inventor before: Zou Yonghua Inventor before: Lu Qinxia Inventor before: Ba Wenjing Inventor before: Pan Chen Inventor before: Xiao yanru |
|
GR01 | Patent grant | ||
GR01 | Patent grant |